Welcome to our dedicated page for Anixa Biosciences news (Ticker: ANIX), a resource for investors and traders seeking the latest updates and insights on Anixa Biosciences stock.
Anixa Biosciences, Inc. reports biotechnology developments tied to the treatment and prevention of cancer. The company's recurring news centers on its investigational breast cancer vaccine, developed with Cleveland Clinic and based on an α-lactalbumin immune-targeting approach, and liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Company updates also cover clinical-trial observations, scientific conference presentations, intellectual-property protection for vaccine technology, manufacturing arrangements for clinical materials, and management presentations describing Anixa's oncology pipeline and business model.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced on July 6, 2020, the completion of the initial drug discovery program in collaboration with OntoChem. They have identified a new compound and several analogs that might inhibit the main protease (Mpro) of a virus. The synthesized compounds are undergoing biological testing, with results expected soon. Additionally, a new in silico library has been created for further evaluation. The company aims to develop inexpensive oral medications for viral treatment, though it remains in the early developmental stages.
Anixa Biosciences, Inc. (NASDAQ: ANIX) has announced a significant realignment of its business strategy to focus exclusively on developing therapeutics and vaccines for high-need patient populations. The company has suspended its Cchek™ liquid biopsy technology. Future efforts will center on cancer immunotherapy in collaboration with Moffitt Cancer Center and a breast cancer vaccine in partnership with Cleveland Clinic. Additionally, Anixa will continue its Covid-19 therapies with OntoChem. CEO Amit Kumar stated that the shift aims to maximize shareholder value amidst evolving market dynamics.